Skip to main content

Good Laboratory Practice (GLP)- Introduction

Good Laboratory Practice (GLP) regulations are a set of quality standards and guidelines that ensure the consistent and reliable conduct of non-clinical laboratory studies. GLP regulations are primarily concerned with the safety testing of pharmaceuticals, chemicals, pesticides, and other products to assess potential risks to human health and the environment. These regulations are essential for generating accurate, reliable, and reproducible data that can be used for regulatory submissions and decision-making.

Key principles of GLP regulations include:

Facilities: GLP regulations specify that laboratories conducting safety studies must have suitable facilities, equipment, and resources to ensure the integrity and validity of the studies. This includes controlled environments, appropriate storage conditions, and well-maintained equipment.

Personnel: Personnel involved in conducting studies must be qualified, trained, and experienced in their respective roles. Job descriptions, training records, and qualifications of individuals are documented to ensure competency.

Standard Operating Procedures (SOPs): Laboratories are required to develop and adhere to detailed SOPs for all study-related activities. SOPs provide step-by-step instructions for processes, ensuring consistency and accuracy across different experiments and studies.

Study Conduct: GLP regulations govern the entire process of conducting studies, from study design and planning to data collection, analysis, and reporting. Studies must be well-documented and performed in compliance with established protocols.

Quality Assurance: Laboratories must have a quality assurance unit responsible for auditing and inspecting study processes to ensure compliance with GLP standards. This unit monitors study conduct, documentation, and overall quality.

Documentation: Accurate, complete, and contemporaneous documentation of all study-related activities, observations, procedures, and results is crucial. Proper documentation ensures traceability, reproducibility, and data integrity.

Data Integrity: Data must be accurate, reliable, and verifiable. Any changes made to data must be documented, justified, and authorized. Original records must be preserved to maintain data integrity.

Archiving: Study records, raw data, and reports must be archived in a secure and organized manner for a defined period. Archiving ensures that data can be retrieved for reference or regulatory inspection.

Reporting: Comprehensive study reports are generated at the conclusion of studies, providing detailed information about the study design, methodology, results, and conclusions. These reports serve as official documentation of study findings.

Inspections: Regulatory authorities conduct routine inspections of laboratories to ensure compliance with GLP regulations. Inspections verify that studies are conducted in accordance with the principles and standards set forth in GLP guidelines.

GLP Guidance Documents

There are several important guidance documents related to Good Laboratory Practice (GLP) that provide detailed information and instructions for complying with GLP regulations. These documents are issued by various regulatory authorities and organizations to assist laboratories and researchers in conducting non-clinical safety studies in accordance with GLP standards. Here are some key GLP guidance documents:

OECD Principles of Good Laboratory Practice: The Organisation for Economic Co-operation and Development (OECD) has developed comprehensive principles and guidelines for GLP, which serve as the international standard. These principles cover various aspects of study conduct, documentation, quality assurance, and compliance.

FDA Guidance for Industry - Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies: The U.S. Food and Drug Administration (FDA) provides guidance to laboratories on GLP compliance. This document outlines the agency's expectations for conducting and documenting nonclinical laboratory studies to support regulatory submissions.

EMA Guidelines on Good Laboratory Practice: The European Medicines Agency (EMA) has issued guidelines that align with OECD principles and provide detailed information on GLP requirements for non-clinical safety studies.

ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals: While not exclusively focused on GLP, this International Council for Harmonisation (ICH) guideline provides recommendations for the nonclinical evaluation of anticancer pharmaceuticals. It covers various aspects, including safety studies, that are conducted in compliance with GLP.

ISO/IEC 17025:2017 - General Requirements for the Competence of Testing and Calibration Laboratories: This ISO standard outlines general requirements for the competence of testing laboratories, including those involved in GLP-compliant studies. It covers aspects such as quality management systems, personnel competence, and reporting.

GLP Compliance Program (FDA): The FDA's compliance program outlines the agency's approach to inspecting laboratories for GLP compliance. It provides insights into how FDA investigators assess laboratories' adherence to GLP regulations.

PIC/S Guide to Good Laboratory Practice (GLP): The Pharmaceutical Inspection Co-operation Scheme (PIC/S) provides guidance on GLP requirements for laboratories involved in the analysis of test items for regulatory submissions.

National Regulatory Authorities: Many countries have their own specific guidance documents related to GLP compliance. These documents provide guidance on how local regulations align with international standards.

These guidance documents offer valuable insights into GLP regulations, standards, and best practices for conducting non-clinical safety studies. Laboratories, researchers, and quality assurance personnel can refer to these documents to ensure that their studies are conducted in accordance with recognized GLP principles and guidelines

Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r
Read more

Cellular & Gene Therapy Guidances (Food and Drug Administration)

  Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry 11/2022 Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry 10/2022 Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry 3/2022 Human Gene Therapy Products Incorporating Human Genome Editing; Draft Guidance for Industry 3/2022 Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry 9/2021 Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency; Guidance for Industry 1/2021 Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry 1/2020 Long Term Follow-up After Administration of Human Gene Therapy Products; Guidance for Industry 1/2020 Testing of Retroviral Vecto
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quantification of si
Read more

Engineering AAV vectors for enhanced safety profiles

 Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti
Read more